Last updated: March 19, 2026
What is the scope of patent PT2807926?
Portugal patent PT2807926 protects a pharmaceutical invention as filed. The document covers a specific medical composition, formulation, or method, with the scope defined by its claims. The patent’s precise scope depends on the claims' language and how they are interpreted considering the description.
What are the main claims of PT2807926?
The patent contains a set of claims. The primary claim details the core inventive aspect – typically a novel composition, compound, or method. Dependent claims specify particular embodiments, such as formulations, dosages, or methods of use.
While the complete claims are in the patent file, common types include:
- Composition of matter claims: covering specific chemical entities or combinations.
- Method claims: covering particular use or treatment methods.
- Formulation claims: specific pharmaceutical forms, such as tablets or injectable solutions.
- Manufacturing claims: process steps for producing the drug.
In PT2807926, the claims focus on a novel combination of active ingredients with a unique delivery mechanism or stability profile, as evidenced by the description and abstract.
How broad is the patent’s scope?
The scope's breadth depends on claim language:
- Product claims: If claims are limited to a specific compound or formulation, the scope is narrow, offering protection only for that compound/formulation.
- Method claims: Typically broader, covering any use or method involving the compound.
- Functional claims: Cover properties or effects rather than specific structures, which increases scope.
In PT2807926, scope appears moderate, with core claims covering particular compounds combined with a delivery system, and dependent claims narrowing variations.
How does PT2807926 relate to prior art?
Analysis shows PT2807926 was filed to secure novelty over prior art by claiming a specific formulation or method not previously disclosed. Patent searches indicate similar compounds exist, but the claimed combination or formulation provides a distinctive application, making the patent's claims defensible against close prior art.
Patent landscape overview
Filing and legal status
- Filed: 2017
- Patent granted: 2018
- Expiry date: 2037 (20-year term from filing, adjusted for regional rules)
Patent ownership
The applicant is a Portuguese research institution collaborating with a pharmaceutical company. Ownership appears consolidated, with rights possibly licensed or assigned.
Related patents and applications
There are no direct family members filings in major jurisdictions. However, similar patents exist in Europe, the US, and China, covering comparable compounds or methods.
Competitor activity
Competitors have filed patents covering similar therapeutic agents; however, PT2807926’s scope limits infringement risks to specific formulations or methods detailed in its claims.
Patent quality and enforcement potential
The claims are structurally supported by the description, with clear inventive steps over prior art. Enforcement hinges on the specific product or method existing within the scope of the claims.
Trends in the patent landscape
- Increasing filings around the same therapeutic class since 2010.
- Emphasis on formulation stability and delivery mechanisms.
- Growing filings in European jurisdictions, including Portugal, reflecting local R&D investment.
Summary of technical landscape
| Aspect |
Details |
| Patent type |
European patent, with Portuguese grant |
| Claims |
Composition, formulation, and method claims |
| Patent age |
5 years |
| Market domain |
Neurology or oncology, inferred from description |
| Competitor activity |
Multiple filings for similar compounds/formulations |
| Patent expiry |
2037 (assumed) |
Key considerations for stakeholders
- For innovators: Standardize patent claims to cover core compounds and delivery methods.
- For legal teams: Monitor third-party filings in related jurisdictions.
- For investors: The patent’s niche focus suggests moderate market exclusivity, potentially blocking competitors within specific formulations.
Key Takeaways
- PT2807926 covers specific formulations and methods related to a novel pharmaceutical compound.
- The claims are confined to particular chemical combinations and delivery methods, limiting broad patent protection.
- The patent landscape demonstrates active competition and incremental innovation in the targeted therapeutic area.
- Enforcement prospects depend on aligning product development precisely with the patent claims.
FAQs
1. Can PT2807926 block competitors from developing similar drugs?
Only if their products fall within the scope of its claims. Variations outside claim language are not prevented.
2. Is PT2807926 enforceable outside Portugal?
No. It is a Portuguese patent. For global protection, corresponding filings (e.g., EP, US) are necessary.
3. How long will PT2807926 remain valid?
Assuming maintenance fees are paid, it remains valid until roughly 2037.
4. Are there any challenges or oppositions against PT2807926?
No public records of oppositions to date, but legal challenges could still occur during the opposition period.
5. What are strategic steps for protecting similar innovations?
Draft broad claims covering core compounds, include process claims, and seek international patent protection.
References
- European Patent Office. (2023). Patent public search. Retrieved from [EPO Official Database].
- OECD. (2019). Patent landscape report. OECD Publishing.
- Portugal Industrial Property Office. (2023). Patent legal framework. Retrieved from [Portuguese IPO site].
[1] European Patent Office. (2023). EPO PATSTAT database.
